Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 13 of 36 for:    DANAZOL

Effects of Telomerase Reactivation With Danazol in Ovarian Function.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04058678
Recruitment Status : Not yet recruiting
First Posted : August 15, 2019
Last Update Posted : August 15, 2019
Sponsor:
Information provided by (Responsible Party):
Juan A Garcia-Velasco, IVI Madrid

Brief Summary:

This project explores the implication of the telomere pathway in ovarian premature and regular aging. Telomere length and maintenance underlie several biological processes such cancer, aging, human diseases and the biology of stem cells. The reactivation of telomerase should lead to a rejuvenation of the ovarian tissue and the improvement of fertility.

The correlation of telomeric factors in blood and granulosa cells will be studied with the aim of finding telomeric biomarkers of ovarian aging.


Condition or disease Intervention/treatment Phase
Ovarian Reserve Drug: Danazol/Placebo Other: Without intervention Not Applicable

Detailed Description:

This is a pilot study, randomized, controled, blind, parallelo arm clinical trial with inactive substance and medicine.

A pilot study will be developed with a total of 45 individuals from 30 to 45 years old, who represent the most frequent population of women seeking for ART.

A control group composed of women with normal ovarian reserve (30 to 45 years old) is needed to compare telomeric and fertility parameters with the group of women with compromised ovarian reserve. Women in the control group irrespective of their age, will have a greater number of follicles compared to women belonging to the group with compromised ovarian reserve.

A group of women with diminished ovarian reserve that will take an inactive substance has been incluided to avoid biases and to set the fertility base line for women with compromised ovarian reserve. The use of an inactive substance or placebo will help obtain better quality results. For instance, if Danazol happened to improve the fertility outcome, then, there could be a possibility that the IVF improvement might be due to other components of the pill. Using placebo, this possibility would be eliminated, since the placebo will contain all components of the pill, except Danazol.

The development of a pilot study will help us understand the statisticl behavior or the telomeric factors as well as to determine the appropriate number of individuals that shoyuld be recruited in a clinical trial to have results with statistical significance. In addition, a pilot study will help us learn errors or undesired events that may happen during the clinical trial. For instance, if patients cannot follow the indications of their doctors and why, or what proportion of patients will drop the study and the reasons for it. Furthermore, it will also help us understand if there exist a tendency, an indication or even a clear beneficial effect for patients without harming them.

The number of participants selected for the study is considered adequate for each group, since each group will be measured in an independent manner.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 45 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: A control group composed of women with normal ovarian reserve to compare telomeric and fertility parameters with the group with compromised ovarian reserve.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:

During the first visist to the doctor, women will be selected according to the selection criteria. Those who seem to have a low ovarian reserve by ultrasound will be informed of the trial, and if they decide to participate, blood will be taken to analyze AMH values. On the second visit, women with low ovarian reserve will be randomized 1:1 for either inactive substance or Danazo, accordint to a computer-generated randomization list prepared by associated statistic. This way, the assigned group will be blind until the momento of executing the randomization procedure. Moment in which, the assigned group will be revealed.

Those with normal ovarian reserve will not be randomized and will just be included as controls.

To maintain the blinding of the trial, Danazol and placebo will be provided in boxs with blisters (PVC opaque and aluminium sealed).

Only the trial medication delegate(s) at the site will dispense the IMP and will know the treatment allocation.

Primary Purpose: Treatment
Official Title: Effects of Telomerase Reactivation With Danazol in Ovarian Function.
Estimated Study Start Date : October 2019
Estimated Primary Completion Date : October 2020
Estimated Study Completion Date : October 2020

Resource links provided by the National Library of Medicine

Drug Information available for: Danazol

Arm Intervention/treatment
Sham Comparator: CONTROL
A control group composed of women with normal ovarian reserve (30 to 45 yerras old) is needed to compare telomeric and fertility parameters with the group of women with compromised ovarian reserve. Note that the term "normal ovarian reserve" referred to older women indicates women that still have follicles in their ovaries -and thus, normal AMH values-, even though the number may be lower tan at a younger age or the quality of oocytes may be lower tan in younger women. In other words, women in the control group irrespective of their age, will have a greater number of follicles compared to women belonging to the group with compromised ovarian reserve.
Other: Without intervention
Women with normal ovarian reserve will not be treated in anyway, thus, randomization will not be necessary.

Experimental: EXPERIMENTAL
A group of women with diminished ovarian reserve that will take an inactive substance has been included to avoik biases and to set the fertility base line for women with compromised ovarian reserve.
Drug: Danazol/Placebo
This group will be randomized 1:1 for either inactive substance or Danazol, according to a computer-generated randomization list prepared. Women will be treated with Danazol/Placebo oral way for 3 months.




Primary Outcome Measures :
  1. Telomere length in granulosa cells [ Time Frame: The evaluation of the main assessment criterion will be done both after eighth visit (36 hours post induction) for women with low ovarian reserve and fifth visit for woman with normal ovarian reserve ]
    Measured in arbitrary units of fluorescence (a.u.) from 0 to 255 gray intensity (8bit) or Kb (continuous variable). Below 3 kb are considered critically short telomeres in humans.


Secondary Outcome Measures :
  1. Accumulation of short telomeres [ Time Frame: Through study completion, an average of 1 year ]
    Measured in arbitrary units of fluorescence (a.u.) from 0 to 255 gray intensity (8bit) or Kb (continuous variable). Below 3 kb are considered critically short telomeres in humans.

  2. Telomerase activity [ Time Frame: Through study completion, an average of 1 year ]
    Product of PCR amplification, run in acrylamide gels and quantified as band intensity (continuous variable)

  3. DNA damage measurement [ Time Frame: Through study completion, an average of 1 year ]
    If damage is positive, then different foci should be apparent in the nucleus of the cell. The number of foci present in the nuclei of at least 100 cells will be counted. If there is DNA damage at telomeres, then yH2AX or 53BPI foci will colocalize with telomeres (labelled with anti TRF1 antibody). Spots will be counted (continuous variable).

  4. Other telomeric factors. [ Time Frame: Through study completion, an average of 1 year ]
    The mRNA expression levels of the telomerase gene and the shelterins, which are involved in telomere lengthening and protection, will be measured by qPCR. (continuous variable).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Most frequent population of women seeking for ART
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Provide signed and dated informed consent form.
  • Willing to comply with all study procedures and be available for the duration of the study. This include the decisión to use contraception methods different to sexual hormones, such as the use of condoms, during the treatment with Danazol.
  • In good general health as evidenced by medical history or diagnosed with body mass index between 18 and 30 kg/m2.
  • Women with normal (AMH valued must be equal or higher tan 2ng/ml) or compromised ovarian reserve (defined as AMH < 2 ng/ml)
  • Not having had any steroid hormones for one month.

Exclusion Criteria:

  • Pregnancy o lactation.
  • Taking other sexual hormones.
  • Women with diseases in heart, liver or kidney or tumors which depend on male sexual hormones or hormone-dependent tumour.
  • Women taking anticonvulsants, medicaments for diabetes, anticoagulants and anti-hypertension: ciclosporin and tacrolimus and other steroids and statins.
  • Women suffering irregular genital bleeding or with thrombus or thromboembolicdiseases.
  • Known allergic reactions to components of the study product (cornstarch and lactose).
  • Having received ovulation induction drugs within one month before the inclusión in the study.
  • Anything that would place the individual at increased risk or preclude the individual´s full compliance with or completion of the study.
  • Simultaneous participation in another clinical trial or previous participation in this study.
  • Participation in another clinical study 2 months before inclusión in the present study that could affect its objectives.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04058678


Contacts
Layout table for location contacts
Contact: Juan Antonio Garcia Velasco 91 180 29 00 juan.garcia.velasco@ivirma.com
Contact: Mónica Toribio Paredes 91 180 29 00 invesmadrid@ivirma.com

Sponsors and Collaborators
IVI Madrid
Investigators
Layout table for investigator information
Principal Investigator: María Elisa Varela IVIRMA MADRID

Publications:
Layout table for additonal information
Responsible Party: Juan A Garcia-Velasco, PhD in Medicine and gynecology, University professor, IVI Madrid
ClinicalTrials.gov Identifier: NCT04058678     History of Changes
Other Study ID Numbers: 1707-FIVI-084-MV
First Posted: August 15, 2019    Key Record Dates
Last Update Posted: August 15, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Juan A Garcia-Velasco, IVI Madrid:
Ovarian reserve.
Telomeric factor
Blood
Granulosa cells
Additional relevant MeSH terms:
Layout table for MeSH terms
Danazol
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs